Research and development of naltrexone: a new narcotic antagonist
Abstract
The author reviews the history of federally supported research in the field of narcotic antagonist therapy, focusing on social, political, and governmental issues. He describes the criteria for establishing an optimum narcotic antagonist, the legal guidelines for drug development, and the currently available narcotic antagonists. Research supported by the National Institute on Drug Abuse has indicated that naltrexone is the most promising drug in this category. The author discusses the safety and clinic use of naltrexone, the status of the NIDA naltrexone program, and plans for future development of the drug.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).